GLP-1 receptor agonists were associated with a lower risk of incident Parkinson's disease compared with sulfonylureas.
Does GLP-1 receptor agonists reduce incident Parkinson's disease in a Scandinavian cohort?
GLP-1 receptor agonists may have a neuroprotective role, as their use is associated with a lower risk of incident Parkinson's disease compared to sulfonylureas.
Absolute Event Rate: 0% vs 0%
In this large observational cohort study, use of GLP-1 receptor agonists compared with sulfonylureas was associated with a lower risk of incident Parkinson's disease. These findings support a potential neuroprotective role of GLP-1 receptor agonists, though replication in additional studies is needed.
Engström et al. (Fri,) reported a other. GLP-1 receptor agonists were associated with a lower risk of incident Parkinson's disease compared with sulfonylureas.